- Home
- AEP vs REGN Comparison
AEP vs REGN Comparison
Compare AEP & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEP | REGN |
|---|---|---|
| Founded | 1906 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0B | 59.5B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | AEP | REGN |
|---|---|---|
| Price | $117.95 | $718.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 23 |
| Target Price | $123.57 | ★ $793.74 |
| AVG Volume (30 Days) | ★ 3.5M | 1.1M |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | ★ 3.23% | 0.49% |
| EPS Growth | ★ 37.44 | 2.88 |
| EPS | 6.83 | ★ 41.59 |
| Revenue | ★ $21,257,000,000.00 | $14,247,800,000.00 |
| Revenue This Year | $9.68 | $1.95 |
| Revenue Next Year | $7.57 | $5.47 |
| P/E Ratio | ★ $17.20 | $17.27 |
| Revenue Growth | ★ 8.44 | 2.89 |
| 52 Week Low | $89.91 | $476.49 |
| 52 Week High | $124.80 | $800.99 |
Technical Indicators
Market Signals| Indicator | AEP | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 54.63 |
| Support Level | $119.59 | $720.07 |
| Resistance Level | $123.90 | $790.98 |
| Average True Range (ATR) | 1.91 | 22.26 |
| MACD | -0.78 | -7.12 |
| Stochastic Oscillator | 8.46 | 26.44 |
Price Performance
Historical ComparisonAbout AEP American Electric Power Company Inc.
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 42% of AEP's capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (21%), nuclear (8%), and demand response (2%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).